264 related articles for article (PubMed ID: 8370162)
1. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.
Chargelegue D; O'Toole CM; Colvin BT
Clin Exp Immunol; 1993 Sep; 93(3):331-6. PubMed ID: 8370162
[TBL] [Abstract][Full Text] [Related]
2. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.
Chargelegue D; Colvin BT; O'Toole CM
AIDS; 1993 Nov; 7 Suppl 2():S87-90. PubMed ID: 7909231
[TBL] [Abstract][Full Text] [Related]
3. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
[TBL] [Abstract][Full Text] [Related]
4. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
[TBL] [Abstract][Full Text] [Related]
5. Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays.
Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Ishikawa E
Clin Diagn Lab Immunol; 2000 Nov; 7(6):872-81. PubMed ID: 11063490
[TBL] [Abstract][Full Text] [Related]
6. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
7. Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.
Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Shimada K; Saito A; Takamizawa A; Shinagawa H; Ishikawa E
J Clin Lab Anal; 1998; 12(2):98-107. PubMed ID: 9524294
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
9. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.
Cheingsong-Popov R; Panagiotidi C; Bowcock S; Aronstam A; Wadsworth J; Weber J
BMJ; 1991 Jan; 302(6767):23-6. PubMed ID: 1899349
[TBL] [Abstract][Full Text] [Related]
10. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
11. More reliable diagnosis of infection with human immunodeficiency virus type 1 (HIV-1) by detection of antibody IgGs to pol and gag proteins of HIV-1 and p24 antigen of HIV-1 in urine, saliva, and/or serum with highly sensitive and specific enzyme immunoassay (immune complex transfer enzyme immunoassay): a review.
Hashida S; Hashinaka K; Ishikawa S; Ishikawa E
J Clin Lab Anal; 1997; 11(5):267-86. PubMed ID: 9292394
[TBL] [Abstract][Full Text] [Related]
12. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.
Koup RA; Pikora CA; Luzuriaga K; Brettler DB; Day ES; Mazzara GP; Sullivan JL
J Exp Med; 1991 Dec; 174(6):1593-600. PubMed ID: 1744586
[TBL] [Abstract][Full Text] [Related]
13. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
14. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
Broliden PA; Morfeldt-Månsson L; Rosen J; Jondal M; Wahren B
Clin Exp Immunol; 1989 May; 76(2):216-21. PubMed ID: 2503275
[TBL] [Abstract][Full Text] [Related]
15. More sensitive immune complex transfer enzyme immunoassay for antibody IgG to p17 of HIV-1 with shorter incubation time for immunoreactions and larger volumes of serum samples.
Ishikawa S; Hashida S; Hashinaka K; Kojima M; Saito A; Takamizawa A; Shinagawa H; Oka S; Shimada K; Ishikawa E
J Clin Lab Anal; 1997; 11(5):244-50. PubMed ID: 9292391
[TBL] [Abstract][Full Text] [Related]
16. The absence of loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1-infected patients.
Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
J Infect Dis; 1995 Sep; 172(3):897-8. PubMed ID: 7658093
[No Abstract] [Full Text] [Related]
17. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection.
Mehta SU; Rupprecht KR; Hunt JC; Kramer DE; McRae BJ; Allen RG; Dawson GJ; Devare SG
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):443-54. PubMed ID: 1692727
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
20. A prospective study on correlation between the decrease in anti-P17 antibody level and progression to AIDS in asymptomatic carriers of HIV.
Choudhury AM; Yamada O; Wakamiya N; Kurimura T
Microbiol Immunol; 1992; 36(8):833-40. PubMed ID: 1474934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
